Provided by Tiger Fintech (Singapore) Pte. Ltd.

XTL Biopharmaceuticals

1.14
+0.00980.87%
Post-market: 1.220.0800+7.02%16:00 EDT
Volume:1.27K
Turnover:1.47K
Market Cap:10.05M
PE:-5.44
High:1.15
Open:1.14
Low:1.14
Close:1.13
Loading ...

Company Profile

Company Name:
XTL Biopharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
5
Office Location:
26 Ben-Gurion St.,Ramat Gan,Israel
Zip Code:
5112001
Fax:
- -
Introduction:
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Directors

Name
Position
Alexander Rabinovich
Non-Executive Director
Dobroslav Melamed
Non-Executive Director
Iris Shapira Yalon
Non-Executive and External Director
Jonathan Schapiro
Non-Executive Director
Osnat Hillel Fain
Non-Executive and External Director
Shlomo Shalev
Non-Executive Director

Shareholders

Name
Position
Doron Turgeman
Chief Executive Officer
Itay Weinstein
Chief Financial Officer